posterpresentation
Description

Title: 3011 - Clinical Evaluation of a Calcium-rich Phosphate Implants

Authors:

Chun-Cheng Hung (Presenter)
Kaohsiung Medical University Hospital

Jen-Chyan Wang, Kaohsiung Medical University Hospital
Wen-Cheng Chen, Feng Chia University
Po-Sung Fu, Kaohsiung Medical University Hospital
Hui-Yu Wu, Kaohsiung Medical University
Chern-Hsiung Lai, Kaohsiung Medical University

Abstract:

Objectives: The aim of this study was to evaluate the clinical efficacy of an innovation developed titanium implant surface treatment by SLA plus with tetracalcium phosphate (TTCP) in clinic trait patients.

Methods: A new Anker II dental implant system (Alliance Global technology Co., LTD, Taiwan) was placed under an IRB approved (KMUH-F (II)-20160092). After CBCT and systemic evaluation, 22 participants (13 women and 9 men) with an average age of 52.35 years received 32 implants. The periapical X ray, probing depth, bleeding on probing and implant stability quotient (ISQ) were monitored during osseointegration at surgical time, 1,2,3 months and post loading at 1,2,3 months. The data were analyzed with the t-test.

Results: The cumulative survival rates were 100%. The maxilla mean buccal site ISQ values at surgical stage and 4-month were 67.40±8.19 and 75.89±3.06, respectively. The mandible mean buccal site ISQ values at surgical stage and 4-month were70.89±5.83 and 77.63±5.93, respectively. The maxilla mean lingual site ISQ values at surgical stage and 4-month were 66.87±9.83 and 75.67±3.43, respectively. The mandible mean lingual site ISQ values at surgical stage and 4-month were 72.63±5.81 and 77.75±6.11, respectively. The all ISQ values were over 65. The probing depth of all implants post loading at 1 month were under 3mm.

Conclusions: This study shows the potential clinical benefits of the TTCP on the titanium implant surface treatment during osseointegration.

This abstract is based on research that was funded entirely or partially by an outside source:
Southern Taiwan Science Park Bureau: CZ-03-03-07-105

Disclosure Statement:
The submitter must disclose the names of the organizations with which any author have a relationship, the nature of the relationship, and the clinical or research area involved. The following is submitted: NONE

Tags